Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | Targeting multiple myeloma antigens

Rakesh Popat • 14 Jun 2019
EHA 2019
Multiple Myeloma

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses target antigens in multiple myeloma, namely CD38 and BCMA, and the rationale behind their therapeutic targeting.This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Rakesh Popat

Oral toxicities associated with talquetamab in RRMM: insights from REALiTAL and TALISMAN 3:11
Oral toxicities associated with talquetamab in RRMM: insights from REALiTAL and TALISMAN
Rakesh Popat • 5 Dec 2025
Patient questionnaire (VRAT) to assess ocular toxicities related to belantamab mafodotin in RRMM 1:38
Patient questionnaire (VRAT) to assess ocular toxicities related to belantamab mafodotin in RRMM
Rakesh Popat • 5 Dec 2025
Sequencing bispecific antibodies and CAR-T in multiple myeloma 1:58
Sequencing bispecific antibodies and CAR-T in multiple myeloma
Rakesh Popat • 5 Dec 2025
Treatment goals and preferences in RRMM: patients and physicians 2:29
Treatment goals and preferences in RRMM: patients and physicians
Rakesh Popat • 20 Sep 2025

Related Videos

Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis 2:35
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
Alexander Lesokhin • 8 Dec 2025
Integrated approaches to improve prognosis prediction in multiple myeloma 2:32
Integrated approaches to improve prognosis prediction in multiple myeloma
Claudio Cerchione • 6 Dec 2025
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals